Recon: Merck says COVID antiviral cut risk of hospitalization, death in Phase 3 trial; Appeals court rules FDA wrongly approved Jacobus' LEMS drug
ReconMichael Mezher
Biologics/ biosimilars/ vaccinesBiotechnologyDiagnostics/IVDsGlobalMedical DevicesNorth AmericaPharmaceuticalsRegulatory Intelligence/Policy